study population (12.75%). Thus we can confirm that the presence of vaginal and cervical ulcers may be considered an additional risk factor for HIV transmission. Although our study was performed on sera belonging to women considered at risk for HIV infections, only 2% of them were certainly infected by HIV-1 and none was infected by HIV-2. This percentage is consistent with another study on an analogous sample of 100 women in February 1993 (data not shown).

During the last 10 years, the war in Angola has greatly limited movement of people between Luanda province and the bordering provinces of Congo, Zaire and Zambia. Probably the low prevalence of HIV in Luanda is due to the partial isolation of the city during the period of HIV pandemic in Sub Sahara Africa.

This work was funded by MURST and DCCS-MAE, Italy (National Laboratory of Public Health, Luanda-programme) and by Ministry of Health, Republic of Angola, AIDS control programme. We are grateful to Dr Antonia Hembie, the directorate and the medical team of Lucrecia Pam Hospital of Luanda and to Dr A Bortolan and Dr G Riva for their helpful collaboration.

P PORTINCASA
T ANNINO
G DETTORI
C CHEZZI
Istituto di Microbiologia,
Università degli Studi di Parma, Italy

N DOS SANTOS
Laboratorio Nacional Saúde Publica,
Luanda, Angola

M VANDUNEN
Maternidade Lucrecia Pam,
Luando, Angola

C LEMOS
World Health Organization,
Luanda, Angola

S RUBINO
P CAPPUCCELLINI
Istituto di Microbiologia e Virologia,
Università degli Studi di Sassari, Italy

M M COLOMBO
Dipartimento di Biologia Cellulare e dello Sviluppo,
Università La Sapienza,
Roma, Italy

Correspondence to: Dr Piero Cappuccellini, Istituto di Microbiologia e Virologia, Viale San Pietro 43B, 07100 Sassari, Italy.


Accepted for publication 12 August 1995

Anaphylaxis due to liposomal amphotericin (AmBisome)

As patients with AIDS are living longer, increasing numbers are developing systemic infections with Cryptococcus neoformans necessitating intravenous amphotericin therapy.

Liposomal amphotericin B (AmBisome) is a recently introduced preparation and is claimed to be less commonly associated with adverse effects than conventional amphotericin B.2 It is therefore a reasonable alternative to use in patients with systemic fungal infection where conventional amphotericin B has been previously associated with renal toxicity.

Two cases of anaphylaxis due to liposomal amphotericin in patients who were not allergic to amphotericin have recently been described.2

We report a further case of anaphylaxis occurring in a patient being given his first injection of AmBisome for treatment of cryptococcal meningitis.

A 28 year old male patient who had been diagnosed HIV positive 9 years previously was admitted with a week’s history of headache, photophobia and vomiting. Cryptococcal meningitis had been successfully treated 9 months previously with conventional intravenous amphotericin B. Subsequently, the patient was maintained on fluconazole but relapsed six months later. Initially, this was treated with intravenous amphotericin B. However, signs of renal toxicity, as shown by rising creatinine and urea, developed after two days and fluconazole was substituted. The patient recovered and again was maintained on fluconazole. After a further month this was changed to itraconazole because of nausea due to fluconazole.

On admission, medication included dapsoine 50mg daily, pyrimethamine 50mg weekly, and itraconazole 400mg daily. CT of the brain was normal and examination of CSF showed 22 white blood cells/mm3 (the majority were lymphocytes) and two yeast cells. Both CSF and serum were positive for cryptococcal antigen. Relapse of cryptococcal meningitis was diagnosed and intravenous liposomal amphotericin B (AmBisome) at a dose of 1mg/kg was commenced. Within seconds of starting the infusion the patient vomited and complained of epigastric pain and abdominal tightness. Bronchospasm, facial flushing and sweating were noted. The infusion was immediately discontinued and symptoms settled within 4 hours. Subsequent treatment comprised of flucytosine and itraconazole and the patient made an uneventful recovery.

It is well recognised that HIV positive patients have a higher incidence of adverse drug reactions compared with the general population and these cases further highlight the need for care to be taken when giving medication to this group of patients.

C M BATES
P B CAREY
Department of Genitoanurourinary Medicine
Lancaster, UK


Accepted for publication 9 August 1995

Pre-treatment with hydration and electrolytes may prevent dose limiting toxicities during foscarnet induction therapy

Foscarnet (Foscavir, Astra Pharmaceuticals) has been used for the treatment of
Eight patients pre-treated with hydration and electrolytes during induction therapy. The mean and the standard deviations of the electrolytes and creatinine, in the patients, before foscarin therapy and after foscarin therapy

<table>
<thead>
<tr>
<th>Electrolytes &amp; creatinine pre-foscarnet</th>
<th>Electrolytes &amp; creatinine after two weeks of foscarin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cr</strong></td>
<td><strong>K</strong></td>
</tr>
<tr>
<td>Mean</td>
<td>0.9</td>
</tr>
<tr>
<td>SD</td>
<td>0.6</td>
</tr>
</tbody>
</table>

Note; Cr = creatinine, ICa = ionised calcium, SD = standard deviation.

cytomegalovirus (CMV) retinitis infection in acquired immunodeficiency syndrome (AIDS). However, the use of foscarin is not without deleterious effects. In using foscarin, the most frequently reported adverse events with electrolytes during five US controlled clinical trials were, (regardless of severity or relationship to foscavir), hypokalaemia (16%), hypocalcaemia (15%), hypomagnesaemia (15%) and seizures (10%). If left untreated depletion of these electrolytes result in neurological, cardiovascular and musculoskeletal sequelae.

Deray et al demonstrated, that adequate hydration prior to foscarin infusion could negate nephrotoxicity almost completely. The electrolyte imbalances with foscarin therapy are more complex. Concomitant replacement of electrolytes consisting of calcium, potassium, magnesium and phosphate could prevent potentially life threatening conditions. However, pre-treatment has not been reported before. As there are no definite guidelines on the doses of electrolytes to be used in pre-treatment, we conducted a non-randomised, open label study on eight patients receiving induction therapy with foscarin for CMV retinitis. The aim of the study was to assess the safety of pre-treatment with electrolytes, and to evaluate its effects on the dose-limiting electrolyte abnormalities seen with foscarin induction therapy. The doses of electrolytes selected were based upon our previous experience with electrolyte replacement used in patients treated with foscarin.

Eight patients with CMV retinitis needing foscarin therapy were prospectively evaluated. All patients were infused with foscarin 90 mg/kg every 12 hours for 2 weeks. The patients were hydrated with 2 l of 0.9% saline a day and received 1 g of MgSO4 and 24 mMol of K2PO4 each day IV, and calcium carbonate 1 g PO each day for the first week. In the second week the K2PO4 was changed to KCl 20 meq/day. Patients on intravenous hyperalimentation received similar replacements. Serum electrolytes were measured before foscarin induction therapy, followed by twice a week during the induction period, and after completing induction therapy (table). All patients tolerated the therapy well and there were no dose limiting electrolyte abnormalities.

Foscarnet is effective against CMV and most other herpes viruses. It is also known to demonstrate some activity against human immunodeficiency virus type 1 (HIV-1).

Most physicians treating CMV may be reluctant to use foscarin because of the electrolyte abnormalities, and the resultant sequelae. The present observational study suggests, that electrolytes may be safely administered with induction doses of foscarin, before electrolyte abnormalities occur, and may prevent dose limiting toxicities. Studies are presently underway to determine if the oral route may be substituted for intravenous, for hydration and electrolyte replacement.

DUSHYANTHA T JAYAWEEARAGINA WHITE*JOSE MORENO The Section of Special Immunology, University of Miami School of Medicine, and the Department of Pharmacy, Jackson Memorial Hospital*, Miami, Florida, USA

Address correspondence to: D T Jayaweera MD, University of Miami School of Medicine, Section of Special Immunology (D90A), PO Box 016990, Miami, Florida 33101, USA

2 Foscarnet package insert.

Accepted for publication 5 September 1995.
Pre-treatment with hydration and electrolytes may prevent dose limiting toxicities during foscarnet induction therapy.

D Jayaweera, G White and J Moreno

doi: 10.1136/sti.71.6.414-a

Updated information and services can be found at: http://sti.bmj.com/content/71/6/414.2.citation

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/